An interventional study of Mindfulness and Relapse Prevention in Alcohol Abuse and Criminal Behavior, sponsored by The Mind Research Network. Completed at 1 site in United States. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by The Mind Research Network · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,076 studies in Alcoholism with a site in United States — 190 open to participants now, 230 under way, 16 of them phase 3. Alcoholism · United States.
Among the 1,076 studies in Alcoholism with a site in United States, this one is the 236th largest by enrollment of the 992 interventional ones that give a count, is one of 50 that started in 2018, is one of 436 with no phase, and was the 656th registered.
1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.
Browse Alcoholism studies →190 of the 1,076 studies in Alcoholism with a site in United States are open now. Recruiting first, the newest first:
Washington State University · Sites in United States
Ages 18+
University of Pennsylvania · Sites in United States
Ages 21–65
National Institute on Drug Abuse (NIDA) · Sites in United States
Ages 18–120
National Institute on Drug Abuse (NIDA) · Sites in United States
Ages 21–100 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,076 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 139 · Phase 2 313 · Phase 3 78 · Phase 4 96
First in 1992; this study’s year is marked. 50 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 176 is above the median of 88 across 1,433 interventional studies indexed under Alcoholism.
Median enrollment 80 across the 992 interventional studies, 109 across the 79 observational. Of the 780 that completed or were terminated, 372 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 1,076 have an industry lead sponsor. The 10 most frequent:
The Mind Research Network is the lead sponsor of 18 studies on the registry; 5 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
The Mind Research Network has 8 studies filed under Alcoholism — fewer than ten, so there is no comparison to draw.
83 of the studies in Alcoholism with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06173973Phase 3University of PennsylvaniaEffects of Ketone Supplementation on Acute Alcohol Withdrawal | 2026-12 |
| NCT05015881Phase 3University of PennsylvaniaRelationship Between Brain and Heart Glucose Metabolism in Alcohol Use Disorder | 2026-12 |
| NCT04616781Phase 3University of PennsylvaniaKetone Ester Intervention in Alcohol Use Disorder | 2026-12 |
| NCT06702007Phase 3University of WashingtonElectronic Harm Reduction Treatment for Alcohol | 2027-01 |
| NCT05613608Phase 3University of Colorado, DenverAlcohol Use Disorder and Cannabidiol | 2027-04 |
Add all 83 to your calendar (.ics) → With an account.
Among the 1,076 studies in Alcoholism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Over half of state and federal prisoners meet clinical criteria for alcohol abuse or dependence, and after release from prison, over three-quarters of offenders are re-arrested within five years. Thus, there is a critical need for more effective interventions that could help disrupt this insidious cycle of alcohol abuse, criminal behavior, and incarceration. This project will support the development and evaluation of a mindfulness intervention for female prison inmates that will target key neuropsychological vulnerabilities that are associated with relapse and recidivism.
The pernicious link between substance abuse and criminal behavior imposes major costs to society, totaling billions of dollars in the U.S. annually. There is a critical need for more effective interventions to counteract the high rates of relapse and recidivism in alcohol and substance abusing criminal offenders. Periods of offender incarceration provide a unique opportunity to develop and deploy such interventions. Progress in intervention development could be achieved by targeting specific cognitive and affective vulnerabilities that are common among substance abusing criminal offenders. Preliminary studies suggest that meditative or mindfulness interventions may confer significant psychological and behavioral benefits to inmates. However, the mechanisms and extent of intervention efficacy are unclear, as these previous studies have been beset by a number of methodological limitations. Moreover, to date no study has examined the neurobiological mechanisms that relate to treatment success in this population. NIAAA has recently made a program call to address these issues (PA-15-299). Here we answer this program call and propose to undertake a rigorous and comprehensive longitudinal study of mindfulness treatment of alcohol and substance use disorders among female inmates. This project will randomly assign over 400 female inmates to a mindfulness or relapse prevention training course, and both will be compared against a no treatment control. The mindfulness intervention will be tailored to address two key neuropsychological deficits in alcohol abusing criminal offenders: impulsivity and craving. We will test hypotheses about the neural changes over time with treatment to elucidate mechanisms of change. We will obtain estimates of "real-world" efficacy of the intervention by collecting outcome measures in prison (conduct reports) and following release (alcohol use relapse and antisocial behavior). This project takes advantage of a unique, longstanding partnership between the research team and the states of New Mexico and Wisconsin Correction Departments that allows collection of comprehensive assessment data from inmates during incarceration, including brain imaging data with a mobile MRI scanner, as well as access to post-release outcomes and relapse data. Completion of these aims is a critical step for implementing and evaluating a promising mindfulness intervention for this high-risk population. The proposed research will also begin to elucidate the psychological and neurobiological mechanisms of the treatment. These results will thus significantly advance a program of research seeking to translate the growing knowledge of neuropsychological deficits into more targeted and effective treatments for alcohol and substance abuse problems in criminal offenders.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Mindfulness
Behavioral: Mindfulness
Behavioral: Relapse Prevention
Mindfulness-based Relapse Prevention. Guided meditation/discussion (Group sessions).
Relapse Prevention. Cognitive behavioral principles/strategies (Group sessions).
Change From Baseline Alcohol Craving
Penn Alcohol Craving Scale. 5-item, self-report measure assessing frequency, intensity, and duration of craving, and overall rating of craving for the previous week. Total score range 0-30. Higher scores indicate higher craving.
Time frame: Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.
Change From Baseline Daily Depression
Beck Depression Inventory-II (BDI-II). Assesses participants' self-reported depression in the past two weeks. Data for total scores is provided (range: 0-63). Higher scores indicate increased severity of depressive symptoms.
Time frame: Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.
Change From Baseline Perception of Quality of Life
World Health Organization Quality of Life - Brief (WHOQOL-BREF). 26-item, self-report measure assessing how individuals perceive their quality of life across domains. Data for psychological health is reported (range: 6-30). Higher scores indicate increased psychological health.
Time frame: Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.
Proportion of Participants Who Were Not Arrested Following Release From Incarceration
Arrests on misdemeanor and felony charges were the categories used to track criminal behavior in the study participants. To evaluate the effect of the treatment on criminal behavior, we used official state databases to track criminal activity for participants who were released from incarceration post-treatment.
Time frame: 30 months following release from incarceration; misdemeanor and felony arrests were cataloged across the treatment arms.
Participant Reflections on Their Treatment Program
During the last session of treatment, participants were given a "Reflections on the Course" handout, where they provided feedback on the treatment they received. Participants were asked to provide a rating to the following question: * Question 1: On a scale of 1 (not at all) to 10 (very), how important has this program been to you?
Time frame: Post-treatment (immediately after 8-week treatment ended)
Investigate Behavioral and Neural Changes Related to Alcohol Craving During Treatment
Salience Alcohol Task (SAT): A drug-cue reactivity functional Magnetic Resonance Imaging (fMRI) task, whereby participants viewed different stimuli (i.e., alcohol cues, negatively valanced stimuli, or neutrally valanced stimuli). After seeing each image, participants were asked to respond to which type of image they saw (i.e., alcohol cues, neutral cues, and negatively valanced cues). Participants completed this task pre-/post-treatment. Independent component analysis was used to extract brain regions related to alcohol cue reactivity, in order to assess functional connectivity changes related to treatment between these regions. Values below represent positive change in z-scores (post - pre-treatment) related to increased functional network connectivity between the anterior cingulate cortex and anterior insula, regions commonly involved in salience detection. A z-score of 0 represents the population mean. All four groups showed increased functional connectivity with z-scores above 0.
Time frame: Baseline (before treatment) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given scans at the same timeframe as those who participated in treatment.
| Milestone | Mindfulness | Relapse Prevention | Waitlist Control | Treatment as Usual |
|---|---|---|---|---|
| Started | 80 | 77 | 8 | 11 |
| Completed | 61 | 67 | 8 | 11 |
| Not completed | 19 | 10 | 0 | 0 |
Penn Alcohol Craving Scale. 5-item, self-report measure assessing frequency, intensity, and duration of craving, and overall rating of craving for the previous week. Total score range 0-30. Higher scores indicate higher craving.
| score on a scale | Mindfulness | Relapse Prevention | Waitlist Control | Treatment as Usual |
|---|---|---|---|---|
| Change From Baseline Alcohol Craving | -2.73 ± 6.47 | -1.75 ± 6.34 | -4.29 ± 8.77 | 1.88 ± 6.08 |
Beck Depression Inventory-II (BDI-II). Assesses participants' self-reported depression in the past two weeks. Data for total scores is provided (range: 0-63). Higher scores indicate increased severity of depressive symptoms.
| score on a scale | Mindfulness | Relapse Prevention | Waitlist Control | Treatment as Usual |
|---|---|---|---|---|
| Change From Baseline Daily Depression | -5.29 ± 7.92 | -7.12 ± 9.88 | -15.43 ± 10.47 | 4.00 ± 10.07 |
World Health Organization Quality of Life - Brief (WHOQOL-BREF). 26-item, self-report measure assessing how individuals perceive their quality of life across domains. Data for psychological health is reported (range: 6-30). Higher scores indicate increased psychological health.
| score on a scale | Mindfulness | Relapse Prevention | Waitlist Control | Treatment as Usual |
|---|---|---|---|---|
| Change From Baseline Perception of Quality of Life | 0.56 ± 1.62 | 0.44 ± 1.52 | 0.76 ± 1.05 | 0.25 ± 2.28 |
Arrests on misdemeanor and felony charges were the categories used to track criminal behavior in the study participants. To evaluate the effect of the treatment on criminal behavior, we used official state databases to track criminal activity for participants who were released from incarceration post-treatment.
| proportion of participants | Mindfulness | Relapse Prevention | Waitlist Control | Treatment as Usual |
|---|---|---|---|---|
| Proportion of Participants Who Were Not Arrested Following Release From Incarceration | 0.873 (0.76 to 1.00) | 0.689 (0.53 to 0.89) | 0.857 (0.63 to 1.00) | 1.00 (1.00 to 1.00) |
During the last session of treatment, participants were given a "Reflections on the Course" handout, where they provided feedback on the treatment they received. Participants were asked to provide a rating to the following question: * Question 1: On a scale of 1 (not at all) to 10 (very), how important has this program been to you?
| score on a scale | Mindfulness | Relapse Prevention | Waitlist Control | Treatment as Usual |
|---|---|---|---|---|
| Participant Reflections on Their Treatment Program | 9.00 ± 1.33 | 9.03 ± 1.10 | — | — |
Salience Alcohol Task (SAT): A drug-cue reactivity functional Magnetic Resonance Imaging (fMRI) task, whereby participants viewed different stimuli (i.e., alcohol cues, negatively valanced stimuli, or neutrally valanced stimuli). After seeing each image, participants were asked to respond to which type of image they saw (i.e., alcohol cues, neutral cues, and negatively valanced cues). Participants completed this task pre-/post-treatment. Independent component analysis was used to extract brain regions related to alcohol cue reactivity, in order to assess functional connectivity changes related to treatment between these regions. Values below represent positive change in z-scores (post - pre-treatment) related to increased functional network connectivity between the anterior cingulate cortex and anterior insula, regions commonly involved in salience detection. A z-score of 0 represents the population mean. All four groups showed increased functional connectivity with z-scores above 0.
| z-scored functional connectivity value | Mindfulness | Relapse Prevention | Waitlist Control | Treatment as Usual |
|---|---|---|---|---|
| Investigate Behavioral and Neural Changes Related to Alcohol Craving During Treatment | 0.05 ± 0.43 | 0.01 ± 0.33 | 0.04 ± 0.36 | 0.06 ± 0.48 |
Collected over We monitored participants from the time they were consented to the study through their active study participation (3 years).. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mindfulness | 0/80 (0%) | 0/80 (0%) | 0/80 (0%) |
| Relapse Prevention | 0/77 (0%) | 0/77 (0%) | 0/77 (0%) |
| Waitlist Control | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Treatment as Usual | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) |
| Age, Continuous(years) | Mindfulness | Relapse Prevention | Waitlist Control | Treatment as Usual | Total |
|---|---|---|---|---|---|
| Mean | 35.88 ± 8.32 | 37.75 ± 8.47 | 32.38 ± 3.50 | 37.82 ± 8.26 | 36.66 ± 8.28 |
| Sex: Female, Male(Participants) | Mindfulness | Relapse Prevention | Waitlist Control | Treatment as Usual | Total |
|---|---|---|---|---|---|
| Female | 80 | 77 | 8 | 11 | 176 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Mindfulness | Relapse Prevention | Waitlist Control | Treatment as Usual | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 36 | 36 | 5 | 2 | 79 |
| Not Hispanic or Latino | 44 | 41 | 3 | 9 | 97 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Mindfulness | Relapse Prevention | Waitlist Control | Treatment as Usual | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 11 | 9 | 2 | 0 | 22 |
| Asian | 1 | 1 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 5 | 1 | 1 | 12 |
| White | 48 | 44 | 3 | 10 | 105 |
| More than one race | 3 | 1 | 0 | 0 | 4 |
| Unknown or Not Reported | 12 | 17 | 2 | 0 | 31 |
| Region of Enrollment(participants) | Mindfulness | Relapse Prevention | Waitlist Control | Treatment as Usual | Total |
|---|---|---|---|---|---|
| United States | 80 | 77 | 8 | 11 | 176 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2018 to primary completion in Apr 2025, 81 months.
Results were first posted in Nov 2026, 1 year 6 months after primary completion.
Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's 81 months is above that.
Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Mind Research Network